FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Pazdur Warns About Political Interference, Upheaval At FDA

[ Price : $8.95]

Former FDA Oncology Center for Excellence director Richard Pazdur warns that political interference and internal upheaval are erod...

FDA Extends Review for Filspari in Kidney Disease

[ Price : $8.95]

FDA extends by three months its review of a Travere Therapeutics supplemental NDA for Filspari in focal segmental glomeruloscleros...

Baxter Class 1 Recall of Sigma Infusion Pumps

[ Price : $8.95]

FDA classifies as Class 1 a recall of certain Sigma Spectrum infusion pumps made by Baxter, warning that continued use of the affe...

35 Items on CDER CY2026 Guidance Agenda

[ Price : $8.95]

CBER says it expects to publish 35 draft and final guidances this calendar year, including several likely-to-be controversial draf...

Remove Suicide Warning from GLP-1 Drugs: FDA

[ Price : $8.95]

FDA says Novo Nordisk and Lilly should remove statements about the potential for suicidal ideation and behavior from labeling for ...

Flexible Regulatory Approaches for Cell/Gene Therapy CMC Info

[ Price : $8.95]

FDA articulates a flexible regulatory approach to chemistry, manufacturing and controls for cell and gene therapies, a move the ag...

Orphan Status for Novita Pancreatic Cancer Drug

[ Price : $8.95]

FDA grants Novita Pharmaceuticals an orphan drug designation for its experimental cancer drug NP-G2-044 for treating pancreatic ca...

Pediatric Menkes Disease Drug Approved

[ Price : $8.95]

FDA approves a Sentynl Therapeutics NDA for Zycubo (copper histidinate) injection as the first treatment for Menkes disease in ped...

FDA 2nd Complete Response on BLA for Atara Cell Therapy

[ Price : $8.95]

FDA issues Pierre Fabre Pharmaceuticals a second Complete Response Letter rejecting its BLA for Atara Biotherapeutics investigatio...

Mifepristones FDA Regulation Driven by Science: JAMA

[ Price : $8.95]

A new JAMA analysis finds that FDAs regulation of mifepristone has been driven largely by scientific evidence and internal expert ...